Literature DB >> 4725366

Schedule-dependent therapeutic synergism for L-asparaginase and methotrexate in leukemic (L5178Y) mice.

S Vadlamudi, B Krishna, V V Reddy, A Goldin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4725366

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  4 in total

1.  Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.

Authors:  Tapan M Kadia; Hagop M Kantarjian; Deborah A Thomas; Susan O'Brien; Zeev Estrov; Farhad Ravandi; Elias Jabbour; Naveen Pemmaraju; Naval Daver; Xuemei Wang; Preetesh Jain; Sherry Pierce; Mark Brandt; Guillermo Garcia-Manero; Jorge Cortes; Gautam Borthakur
Journal:  Am J Hematol       Date:  2014-11-19       Impact factor: 10.047

2.  Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia.

Authors:  Jassada Buaboonnam; Xueyuan Cao; Jennifer L Pauley; Ching-Hon Pui; Raul C Ribeiro; Jeffrey E Rubnitz; Hiroto Inaba
Journal:  Pediatr Blood Cancer       Date:  2013-01-17       Impact factor: 3.167

3.  Refractory acute leukaemia in adults treated with sequential colaspase and high-dose methotrexate.

Authors:  B S Yap; K B McCredie; R S Benjamin; G P Bodey; E J Freireich
Journal:  Br Med J       Date:  1978-09-16

4.  Methotrexate and the need for continued research.

Authors:  F Rosenfelt
Journal:  Yale J Biol Med       Date:  1975-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.